If symptoms are severe or persistent, speak with your clinician
While its safety profile was consistently favorable, the largest Phase IIb trial failed to show statistical significance for weight loss, and commercial development was halted in 2007.[2] Despite this, interest in AOD-9604 has continued in the compounding pharmacy and integrative medicine space, particularly given its safety data, its lack of IGF-1 stimulation, and emerging research around joint health
Use within 90 days after reconstitution
J Biol Chem 278:4853448545
Insert the needle using a smooth, dart-like motion until it reaches the muscle
Functional properties and mode of regulation of the mitochondrial Na(+)/Ca(2+) exchanger, NCLX